TRIAL IN PROGRESS: PHASE I DOSE-ESCALATION STUDY OF VSV-GP (BI 1831169) MONOTHERAPY AND WITH EZABENLIMAB (BI 754091) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

被引：0
|
作者：
Porosnicu, Mercedes [1 ]
Quinson, Anne-Marie [2 ]
MacKay, Abi [3 ]
Luecke, Stephan [4 ]
Lauer, Ulrich M. [5 ]
机构：
[1] Wake Forest Sch Med, Winston Salem, NC USA
[2] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Univ Tubingen Hosp, Tubingen, Germany
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
628
引用
收藏
页码：A660 / A660
页数：1
相关论文
共 50 条
  • [11] A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors
    De Braud, Filippo G.
    Cascinu, Stefano
    Spitaleri, Gianluca
    Pilz, Korinna
    Clementi, Laura
    Liu, Dan
    Glomb, Patricia
    De Pas, Tommaso
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [12] A FIRST-IN-HUMAN PHASE I DOSE-ESCALATION TRIAL OF THE B7-H6/CD3 T-CELL ENGAGER BI 765049 ± EZABENLIMAB (BI 754091) IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING B7-H6
    Falchook, Gerald
    Spigel, David
    Patel, Manish
    Bashir, Babar
    Ulahannan, Susanna
    Duffy, Christine
    Maier, Daniela
    Azuma, Hisaya
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A510 - A510
  • [13] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [14] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [15] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [16] A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6
    Falchook, Gerald Steven
    Patel, Manish R.
    Ulahannan, Susanna Varkey
    Maier, Daniela
    Hipp, Susanne
    Azuma, Hisaya
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [17] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Véronique Diéras
    Thomas Bachelot
    Mario Campone
    Nicolas Isambert
    Florence Joly
    Christophe Le Tourneau
    Philippe Cassier
    Emmanuelle Bompas
    Pierre Fumoleau
    Sabine Noal
    Christine Orsini
    Marta Jimenez
    Diane Charlotte Imbs
    Etienne Chatelut
    Oncology and Therapy, 2016, 4 (2) : 211 - 223
  • [18] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Dieras, Veronique
    Bachelot, Thomas
    Campone, Mario
    Isambert, Nicolas
    Joly, Florence
    Le Tourneau, Christophe
    Cassier, Philippe
    Bompas, Emmanuelle
    Fumoleau, Pierre
    Noal, Sabine
    Orsini, Christine
    Jimenez, Marta
    Imbs, Diane Charlotte
    Chatelut, Etienne
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 211 - 223
  • [19] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [20] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
12345